|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 胆道肿瘤临床实践指南(英文第三版)显示文摘日本肝胆胰外科学会(JSHBPS)于2007年出版第一版胆道肿瘤(胆管癌、胆囊癌及壶腹癌)临床实践指南,于2014年更新第二版,2021年英文第三版胆道肿瘤临床实践指南围绕6个主题提出若干临床问题,基于相关循证医学证据并组织专家讨论后,最终确定推荐意见、推荐强度以及推荐说明。根据证据推荐分级的评估、制订与评价(GRADE)系统,推荐强度被分为1级(强)或者2级(弱)。英文第三版胆道肿瘤临床实践指南中提出的31个临床问题涵盖:(1)预防性治疗;(2)诊断;(3)胆道引流;(4)外科治疗;(5)化疗;(6)放疗。31个临床问题中,14个问题给予推荐强度为强的推荐意见,14个问题给予推荐强度为弱的推荐意见,剩余的3个问题未给予推荐意见。每条推荐意见都进行推荐强度说明。最新版指南基于循证医学证据,为临床提供了重要建议。未来与癌症登记数据库协作将是评估指南和建立新证据的关键。 | Masato Nagino Satoshi Hirano Hideyuki Yoshitomi Taku Aoki Katsuhiko Uesaka Michiaki Unno Tomoki Ebata Masaru Konishi Keiji Sano Kazuaki Shimada Hiroaki Shimizu Ryota Higuchi Toshifumi Wakai Hiroyuki Isayama Takuji Okusaka Toshio Tsuyuguchi Yoshiki Hirooka Junji Furuse Hiroyuki Maguchi Kojiro Suzuki Hideya Yamazaki Hiroshi Kijima Akio Yanagisawa Masahiro Yoshida Yukihiro Yokoyama Takashi Mizuno Itaru Endo 杨翼飞(译) 仇毓东(译) 赵梦珂(译) 伏旭(译) 蔡正华(译) 毛凉(审校) | 2021 | 中华消化外科杂志2021，20，4： | 7 |
| 2 | Usefulness of urinary trypsinogen-2 and trypsinogen activation peptide in acute pancreatitis:A multicenter study in Japan显示文摘BACKGROUND Rapid urinary trypsinogen-2 dipstick test and levels of urinary trypsinogen-2 and trypsinogen activation peptide(TAP) concentration have been reported as prognostic markers for the diagnosis of acute pancreatitis.AIM To reconfirm the validity of all these markers in the diagnosis of acute pancreatitis by undertaking a multi-center study in Japan.METHODS Patients with acute abdominal pain were recruited from 17 medical institutions in Japan from April 2009 to December 2012. Urinary and serum samples were collected twice, at enrollment and on the following day for measuring target markers. The diagnosis and severity assessment of acute pancreatitis were assessed based on prognostic factors and computed tomography(CT) Grade of the Japanese Ministry of Health, Labour, and Welfare criteria.RESULTS A total of 94 patients were enrolled during the study period. The trypsinogen-2 dipstick test was positive in 57 of 78 patients with acute pancreatitis(sensitivity,73.1%) and in 6 of 16 patients with abdominal pain but without any evidence of acute pancreatitis(specificity, 62.5%). The area under the curve(AUC) score of urinary trypsinogen-2 according to prognostic factors was 0.704, which was highest in all parameter. The AUC scores of urinary trypsinogen-2 and TAP according to CT Grade were 0.701 and 0.692, respectively, which shows higher than other pancreatic enzymes. The levels of urinary trypsinogen-2 and TAP were significantly higher in patients with extended extra-pancreatic inflammation as evaluated by CT Grade.CONCLUSION We reconfirmed urinary trypsinogen-2 dipstick test is useful as a marker for the diagnosis of acute pancreatitis. Urinary trypsinogen-2 and TAP may be considered as useful markers to determine extra-pancreatic inflammation in acute pancreatitis. | Hiroaki Yasuda Keisho Kataoka Yoshifumi Takeyama Kazunori Takeda Tetsuhide Ito Toshihiko Mayumi Shuji Isaji Tetsuya Mine Motoji Kitagawa Seiki Kiriyama Junichi Sakagami Atsushi Masamune Kazuo Inui Kenji Hirano Ryukichi Akashi Masamichi Yokoe Yoshio Sogame Kazuichi Okazaki Chie Morioka Yasuyuki Kihara Shigeyuki Kawa Masao Tanaka Akira Andoh Wataru Kimura Isao Nishimori Junji Furuse Isao Yokota Tooru Shimosegawa | 2019 | World Journal of Gastroenterology2019，25，1： | 7 |
| 3 | Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma显示文摘 | Masatoshi Kudo Kazuho Imanaka Nobuyuki Chida Kohei Nakachi Won-Young Tak Tadatoshi Takayama Jung-Hwan Yoon Takeshi Hori Hiromitsu Kumada Norio Hayashi Shuichi Kaneko Hirohito Tsubouchi Dong Jin Suh Junji Furuse Takuji Okusaka Katsuaki Tanaka Osamu Matsui | 2011 | European Journal of Cancer2011，，14： | 5 |
| 4 | Familial pancreatic cancer: Concept, management and issues显示文摘Familial pancreatic cancer (FPC) is broadly defined as two first-degree-relatives with pancreatic cancer (PC) and accounts for 4%-10% of PC. Several genetic syndromes, including Peutz-Jeghers syndrome, hereditary pancreatitis, hereditary breast-ovarian cancer syndrome(HBOC), Lynch syndrome, and familial adenomatous polyposis (FAP), also have increased risks of PC, but the narrowest definition of FPC excludes these known syndromes. When compared with other familial tumors, proven genetic alterations are limited to a small proportion (<20%) and the familial aggregation is usually modest. However, an ethnic deviation (Ashkenazi Jewish>Caucasian) and a younger onset are common also in FPC. In European countries, 'anticipation' is reported in FPC families, as with other hereditary syndromes; a trend toward younger age and worse prognosis is recognized in the late years. The resected pancreases of FPC kindred often show multiple pancreatic intraepithelial neoplasia (Pan IN) foci, with various K-ras mutations, similar to colorectal polyposis seen in the FAP patients. As with HBOC patients, a patient who is a BRCA mutation carrier with unresectable pancreatic cancer (accounting for 0%-19% of FPC patients) demonstrated better outcome following platinum and Poly (ADP-ribose) polymerase inhibitor treatment. Western countries have established FPC registries since the 1990 s and several surveillance projects for highrisk individuals are now ongoing to detect early PCs. Improvement in lifestyle habits, including non-smoking, is recommended for individuals at risk. In Japan, the FPC study group was initiated in 2013 and the Japanese FPC registry was established in 2014 by the Japan Pancreas Society. | Hiroyuki Matsubayashi Kyoichi Takaori Chigusa Morizane Hiroyuki Maguchi Masamichi Mizuma Hideaki Takahashi Keita Wada Hiroko Hosoi Shinichi Yachida Masami Suzuki Risa Usui Toru Furukawa Junji Furuse Takamitsu Sato Makoto Ueno Yoshimi Kiyozumi Susumu Hijioka Nobumasa Mizuno Takeshi Terashima Masaki Mizumoto Yuzo Kodama Masako Torishima Takahisa Kawaguchi Reiko Ashida Masayuki Kitano Keiji Hanada Masayuki Furukawa Ken Kawabe Yoshiyuki Majima Toru Shimosegawa | 2017 | World Journal of Gastroenterology2017，23，6： | 5 |
| 5 | Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study显示文摘 | Hedy L Kindler Tatsuya Ioka Dirk J Richel Jaafar Bennouna Richard Létourneau Takuji Okusaka Akihiro Funakoshi Junji Furuse Young Suk Park Shinichi Ohkawa Gregory M Springett Harpreet S Wasan Peter C Trask Paul Bycott Alejandro D Ricart Sinil Kim Eric Van | 2011 | Lancet Oncology2011，，3： | 4 |
| 6 | GIDEON (Global Investigation of therapeutic DE cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis显示文摘 | R. Lencioni M. Kudo S.‐L. Ye J.‐P. Bronowicki X.‐P. Chen L. Dagher J. Furuse J. F. Geschwind L. Ladrón Guevara C. Papandreou T. Takayama S. K. Yoon K. Nakajima R. Lehr S. Heldner A. J. Sanyal | 2014 | Int J Clin Pract2014，，5： | 2 |
| 7 | Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment显示文摘 | Satoshi Kondo Tadahiro Takada Masaru Miyazaki Shuichi Miyakawa Kazuhiro Tsukada Masato Nagino Junji Furuse Hiroya Saito Toshio Tsuyuguchi Masakazu Yamamoto Masato Kayahara Fumio Kimura Hideyuki Yoshitomi Satoshi Nozawa Masahiro Yoshida Keita Wada Satoshi | 2008 | Journal of Hepato - Biliary - Pancreatic Surgery2008，，1： | 2 |
| 8 | Multifunctional strands in tight junctions显示文摘 | TSUKITA S FURUSE M ITOH M | 2001 | Nat Rev Mol Cell Biol2001，2，4： | 1 |
| 9 | A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer显示文摘 | MORIZANE C OKUSAKA T FURUSE J | 2009 | Cancer Chemother Pharmacol2009，63，2： | 1 |
| 10 | Characterization of critical factors influencing gene expression of two types of fatty acid-binding proteins(L-FABP and Lb-FABP) in the liver of birds显示文摘 | Atsushi Murai Mitsuhiro Furuse Kohji Kitaguchi | 2009 | Comparative Bichemistry and Physiology2009，，154： | 1 |
| 11 | Randomized trial of cyclophosphamide,doxorubicin,and vincristine versus cisplatin and etoposide versus alternation of these regiments in small cell lung cancer显示文摘 | Fukuoka M Furuse K Saijo N | 1991 | JNCI1991，83，： | 1 |
| 12 | Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin,vindesine,and cisplatin in unresectable stage Ⅲ non-small cell lung cancer显示文摘 | Furuse K Fukuoka M Kawahara M | 1999 | J Clin Oncol1999，17，： | 1 |
| 13 | A randomized phase Ⅲ study of concurrent vs sequential thoracic radiotherapy in combination with mitomycia,videsine and cisplatin in unresected stage Ⅲ non-small-cell lung cancer:Preliminary analysis(abstract)显示文摘 | Furuse K Fukuoka M Takada Y | 1997 | Proc Am Soc Clin Oncol1997，16，： | 1 |
| 14 | Involvement of claudin-1 in the β-catenin/TCF signaling pathway and its frequent upregulation in human colorectal cancers显示文摘 | Miwa N Furuse M Tsukita S | 2001 | Oncol Res2001，12，1112： | 1 |
| 15 | Respiratory viruses from hospitalized children with severe pneumonia in the Philippines 显示文摘 | Suzuki A Lupisan S Furuse Y | 2012 | BMC Infect Dis2012，12，： | 1 |
| 16 | Mucocele of the gland of Blandin-Nuhn: Histological and clinical findings显示文摘 | De Camargo Moraes P Bonecker M Furuse C | 2009 | Clin Oral Investig2009，13，3： | 1 |
| 17 | Diagnosis of biliary tract and ampullary carcinomas显示文摘 | Kazuhiro Tsukada Tadahiro Takada Masaru Miyazaki Shuichi Miyakawa Masato Nagino Satoshi Kondo Junji Furuse Hiroya Saito Toshio Tsuyuguchi Fumio Kimura Hideyuki Yoshitomi Satoshi Nozawa Masahiro Yoshida Keita Wada Hodaka Amano Fumihiko Miura | 2008 | Journal of Hepato - Biliary - Pancreatic Surgery2008，，1： | 1 |
| 18 | Sorafenib for the treatment of unresectable hepato- cellular carcinoma显示文摘 | Furuse J | 2008 | Biologics2008，12，4： | 1 |
| 19 | Hepatocellular carcinoma with portal vein tumor thrombus embolization of arterioportal shunts显示文摘 | Iwasaki M Yoshino M | 1997 | Radiology1997，204，3： | 1 |
| 20 | Contrast enhancement patterns of hepatic tumours during the vascular phase using coded harmonic imaging and Levovist to differentiate hepatocellular carcinoma from other focal lesions显示文摘 | FURUSE J NAGASE M ISHII H | 2003 | Br J Radiol2003，76，906： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员